Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine

Johnson & Johnson Receives Positive CHMP Opinion for Janssen's Investigational Preventive Ebola Vaccine Regimen (29 May 2020)

Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak, (8 December 2019)

Johnson & Johnson Announces Donation of up to 500,000
Regimens of Janssen’s Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC
), support-outbreak-response-in-democratic-republic-of-thecongo-drc (31 October 2019)

19/12/2015: First encouraging results for EBOVAC on Ebola Vaccine Regimen

The clinical data analysis shows very encouraging results with an antibody response produced by the prime-boost Ebola vaccine regimen in 100 percent of healthy volunteers that was sustained 8 months following immunization. 

View press release here.


08/12/2015: Inserm has launched its campaign to enrol 300 volunteers for Phase 2 trials.

View press release here.


15/07/2015: The University of Oxford has started enrolling volunteers for Phase 2 trials.

View press release here.


16/01/2015: IMI2: First innovative medicines Initiative Ebola projects get underway: 




  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings


Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as NotAllowedScriptReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions